{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=23",
    "query": {
      "intervention": "Period B",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 1574,
    "total_pages": 158,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T21:20:39.696Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05535920",
      "title": "A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "LOKELMA 5 GM Powder for Oral Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NephroNet, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2022-04-14",
      "completion_date": "2024-04-01",
      "has_results": false,
      "last_update_posted_date": "2024-06-05",
      "last_synced_at": "2026-11-03T21:20:39.696Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Lawrenceville, Georgia • Fort Wayne, Indiana + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Asheville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05535920"
    },
    {
      "nct_id": "NCT06715683",
      "title": "A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BMS-986278 Batched method, Dose A",
          "type": "DRUG"
        },
        {
          "name": "BMS-986278 Batched method, Dose B",
          "type": "DRUG"
        },
        {
          "name": "BMS-986278 Continuous method",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2024-12-12",
      "completion_date": "2025-03-16",
      "has_results": false,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-11-03T21:20:39.696Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06715683"
    },
    {
      "nct_id": "NCT01896856",
      "title": "Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Previously Treated Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "SGI-110 Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "TAS-102",
          "type": "DRUG"
        },
        {
          "name": "SGI-110",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2013-10-23",
      "completion_date": "2019-08-26",
      "has_results": true,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-11-03T21:20:39.696Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01896856"
    },
    {
      "nct_id": "NCT07627529",
      "title": "Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson Disease (PD)"
      ],
      "interventions": [
        {
          "name": "Overactive bladder antimuscarinic deprescribing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corporal Michael J. Crescenz VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-06",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-11-03T21:20:39.696Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07627529"
    },
    {
      "nct_id": "NCT02963831",
      "title": "A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Appendiceal Cancer"
      ],
      "interventions": [
        {
          "name": "ONCOS-102",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2017-09-07",
      "completion_date": "2022-06-25",
      "has_results": true,
      "last_update_posted_date": "2022-12-22",
      "last_synced_at": "2026-11-03T21:20:39.696Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Miami, Florida • Buffalo, New York + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02963831"
    },
    {
      "nct_id": "NCT04918147",
      "title": "Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgG4 Related Disease",
        "IgG4-RD"
      ],
      "interventions": [
        {
          "name": "elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "placebo for elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "famotidine",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2021-10-13",
      "completion_date": "2024-01-04",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-11-03T21:20:39.696Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04918147"
    },
    {
      "nct_id": "NCT00366535",
      "title": "Neurotropin Treatment of Fibromyalgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Neurotropin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Nursing Research (NINR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 56,
      "start_date": "2006-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-06-27",
      "last_synced_at": "2026-11-03T21:20:39.696Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00366535"
    },
    {
      "nct_id": "NCT05789537",
      "title": "A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia B with Inhibitor",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "SerpinPC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ApcinteX Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2023-07-28",
      "completion_date": "2025-02-24",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-11-03T21:20:39.696Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Tampa, Florida • Greenville, North Carolina",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05789537"
    },
    {
      "nct_id": "NCT06404047",
      "title": "RECOVER-ENERGIZE Platform Protocol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Long COVID",
        "Long Covid19",
        "Long Covid-19"
      ],
      "interventions": [
        {
          "name": "Personalized Cardiopulmonary Rehabilitation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Structured Pacing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Education",
          "type": "OTHER"
        },
        {
          "name": "Usual Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 660,
      "start_date": "2024-07-17",
      "completion_date": "2025-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-11-03T21:20:39.696Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06404047"
    },
    {
      "nct_id": "NCT01868360",
      "title": "Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Subconjunctival aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Standard of care only",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Balamurali Ambati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2013-06",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2015-10-07",
      "last_synced_at": "2026-11-03T21:20:39.696Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01868360"
    }
  ]
}